- Home
- WRAP vs RGLS Comparison
WRAP vs RGLS Comparison
Compare WRAP & RGLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WRAP
- RGLS
- Stock Information
- Founded
- WRAP 2016
- RGLS 2007
- Country
- WRAP United States
- RGLS United States
- Employees
- WRAP N/A
- RGLS N/A
- Industry
- WRAP Ordnance And Accessories
- RGLS Biotechnology: Pharmaceutical Preparations
- Sector
- WRAP Industrials
- RGLS Health Care
- Exchange
- WRAP Nasdaq
- RGLS Nasdaq
- Market Cap
- WRAP 91.2M
- RGLS 102.1M
- IPO Year
- WRAP N/A
- RGLS 2012
- Fundamental
- Price
- WRAP $2.00
- RGLS $1.26
- Analyst Decision
- WRAP
- RGLS Strong Buy
- Analyst Count
- WRAP 0
- RGLS 6
- Target Price
- WRAP N/A
- RGLS $10.33
- AVG Volume (30 Days)
- WRAP 313.3K
- RGLS 315.1K
- Earning Date
- WRAP 11-14-2024
- RGLS 03-20-2025
- Dividend Yield
- WRAP N/A
- RGLS N/A
- EPS Growth
- WRAP N/A
- RGLS N/A
- EPS
- WRAP N/A
- RGLS N/A
- Revenue
- WRAP $4,231,000.00
- RGLS N/A
- Revenue This Year
- WRAP N/A
- RGLS N/A
- Revenue Next Year
- WRAP N/A
- RGLS N/A
- P/E Ratio
- WRAP N/A
- RGLS N/A
- Revenue Growth
- WRAP N/A
- RGLS N/A
- 52 Week Low
- WRAP $1.21
- RGLS $1.15
- 52 Week High
- WRAP $7.01
- RGLS $3.79
- Technical
- Relative Strength Index (RSI)
- WRAP 55.21
- RGLS 35.32
- Support Level
- WRAP $1.95
- RGLS $1.24
- Resistance Level
- WRAP $2.15
- RGLS $1.40
- Average True Range (ATR)
- WRAP 0.18
- RGLS 0.11
- MACD
- WRAP -0.01
- RGLS -0.03
- Stochastic Oscillator
- WRAP 56.90
- RGLS 19.15
About WRAP Wrap Technologies Inc.
Wrap Technologies Inc offers public safety technologies and services. The firm develops policing solutions to law enforcement and security personnel. Its BolaWRAP 150 Remote Restraint device is a patented, hand-held tool that discharges a Kevlar cord to restrain noncompliant individuals from a range of 10-25 feet. The group operates in the Americas, Europe, the Middle East, Africa and the Asia Pacific.
About RGLS Regulus Therapeutics Inc.
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.